Select Your Location:
Global
France
Switzerland DE | FR | IT

Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)-guided neoadjuvant (n) treatment for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis

Molecule: Tislelizumab

RATIONALE-302 (NCT03430843) is a global Phase 3 study of tislelizumab vs investigator-chosen chemotherapy as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Reading
23 May 2025

RATIONALE-3O3 (NCT03358875) is an open-label, multicenter, randomized study of tislelizumab versus docetaxel in patients with non-small cell lung cancer (NSCLC) who have progressed on a prior platinum-containing regimen.

Reading
23 May 2025

RATIONALE-305 (NCT03777657) is a randomized, double-blind, placebo-controlled, global Phase 3 study of tislelizumab combined with platinum and fluoropyrimidine chemotherapy compared to placebo combined with platinum and fluoropyrimidine chemotherapy as a first-line treatment for patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Reading
23 May 2025